Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 11/20 | 0.78 |
| ▸ | L3MBTL1 | Q9Y468 | 8/20 | 0.78 |
| ▸ | RAD52 | P43351 | 1/20 | 0.78 |
| ▸ | MAPT | P10636 | 10/20 | 0.75 |
| ▸ | NFKB1 | P19838 | 5/20 | 0.75 |
| ▸ | NFKB2 | Q00653 | 5/20 | 0.75 |
| ▸ | RELA | Q04206 | 5/20 | 0.75 |
| ▸ | LMNA | P02545 | 5/20 | 0.75 |
| ▸ | ALOX12 | P18054 | 5/20 | 0.75 |
| ▸ | GAA | P10253 | 5/20 | 0.75 |
| ▸ | TP53 | P04637 | 4/20 | 0.75 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.75 |
| ▸ | BRD4 | O60885 | 1/20 | 0.75 |
| ▸ | ALOX15 | P16050 | 2/20 | 0.74 |
| ▸ | USP2 | O75604 | 1/20 | 0.74 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.67 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.67 |
| ▸ | MPI | P34949 | 2/20 | 0.67 |
| ▸ | SMN1; SMN2 | Q16637 | 8/20 | 0.65 |
| ▸ | HTT | P42858 | 5/20 | 0.65 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5594730 | 0.95 | MAPT (0.76) | KDM4EL3MBTL1RAD52MAPTNFKB1 | |
| SCHEMBL2518179 | 0.93 | KDM4E (0.86) | KDM4EL3MBTL1RAD52MAPTNFKB1 | |
| Hydrochloric Acid SCHEMBL5594620 | 0.91 | KDM4E (0.83) | KDM4EL3MBTL1RAD52MAPTNFKB1 | |
| SCHEMBL13310328 | 0.89 | KDM4E (0.75) | KDM4EL3MBTL1RAD52MAPTNFKB1 | |
| SCHEMBL5594566 | 0.89 | KDM4E (0.89) | KDM4EL3MBTL1RAD52MAPTNFKB1 | |
| SCHEMBL29381869 | 0.88 | KDM4E (0.73) | KDM4EL3MBTL1RAD52MAPTNFKB1 | |
| SCHEMBL113820 | 0.88 | KDM4E (0.73) | KDM4EL3MBTL1RAD52MAPTNFKB1 | |
| SCHEMBL24716091 | 0.87 | KDM4E (0.97) | KDM4EL3MBTL1RAD52MAPTNFKB1 | |
| SCHEMBL30626619 | 0.87 | KDM4E (0.97) | KDM4EL3MBTL1RAD52MAPTNFKB1 | |
| SCHEMBL5595451 | 0.86 | KDM4E (0.75) | KDM4EL3MBTL1RAD52MAPTNFKB1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 39 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1189606-B1 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RES & DEV (IL) | 2007-08-15 | — | — | EP | claimed |
| US-6855711-B1 | Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-02-15 | — | — | US | claimed |
| EP-1189606-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2002-03-27 | — | — | EP | claimed |
| WO-2000074664-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-12-14 | — | — | WO | claimed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-9302993-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2016-04-05 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-11-26 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9169211-B2 | 8-hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2015-10-27 | — | — | US | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-9163018-B2 | Method of treatment of age-related macular degeneration (AMD) | PRANA BIOTECHNOLOGY INC. (AU) | 2015-10-20 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PRANA BIOTECHNOLOGY LIMITED (AU) | 2008-07-03 | — | — | US | disclosed |
| WO-2007118276-A1 | METHOD OF TREATMENT OF AGE-RELATED MACULAR DEGENERATION(AMD) | PRANA BIOTECHNOLOGY LTD (AU) | 2007-10-25 | — | — | WO | disclosed |
| EP-1189606-B1 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RES & DEV (IL) | 2007-08-15 | — | — | EP | disclosed |
| US-6855711-B1 | Pharmaceutical compositions comprising iron chelators for the treatment of neurodegenerative disorders and some novel iron chelators | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2005-02-15 | — | — | US | disclosed |
| WO-2004007461-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PRANA BIOTECHNOLOGY LIMITED (AU) | 2004-01-22 | — | — | WO | disclosed |
| EP-1189606-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT Co. LTD. (IL) | 2002-03-27 | — | — | EP | disclosed |
| WO-2000074664-A2 | NOVEL IRON CHELATORS AND PHARMACEUTICAL COMPOSITIONS COMPRISING IRON CHELATORS FOR THE TREATMENT OF NEURODEGENERATIVE DISORDERS | YEDA RESEARCH AND DEVELOPMENT CO. LTD. (IL) | 2000-12-14 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150335635-A1 | 8-HYDROXY QUINOLINE DERIVATIVES | PARK7, COQ8A, NLN | KDM4E 3604/4885L3MBTL1 3725/4885RAD52 2511/4885 |
| US-20080161353-A1 | 8-Hydroxy quinoline derivatives | PARK7, COQ8A, NLN | KDM4E 3604/4885L3MBTL1 3725/4885RAD52 2511/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.